Shanghai Henlius Biotech, Inc. - H Shares Stock: price and insider trades · Hong Kong
1 insider bought €113k of shares over the last 90 days, the latest by Zhu Jun, filed 12 Oct 2026.
Shanghai Henlius Biotech, Inc. - H Shares: what insiders have been doing
Shanghai Henlius Biotech, Inc. - H Shares is a Health Care company. Its directors and officers file their transactions with HKEX. From 22 October 2025 to 22 October 2026, the disclosure feed for Shanghai Henlius Biotech, Inc. - H Shares logged 13 filings by 5 insiders.
Both sides are active: 2 purchases worth €113k and 6 sales worth €702k, from 1 insider and 5 insiders respectively. The totals do not cover 2 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive. Zhu Jun filed the largest sale, €670k, on 10 July 2026, which represents 0.019% of the company's market value.
The last insider purchase was made public on 12 October 2026, 27 days ago. The median gap between a trade and its publication by HKEX is 5 days. This delay matters because a trade only becomes useful information once it is public. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 1,314 companies tracked on its exchange, the median is 4 filings; at 13 filings, this issuer sits above that mark. The full history, which starts in 2026, counts 2 purchases against 6 sales.
Other companies in the same sector with recent insider buying flagged by our signals: UCB. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- +1.9%Entry HK$52.70 · Close 21 Oct 2026 HK$53.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Shanghai Henlius Biotech, Inc. - H Shares Strong Buy (bullish), based on 7 analysts. Average price target: HK$102.91.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 20,000 shares@ HK$49.920.0035% mcap14.5% of flowShareXHKGHKEX:DA20261012E00030Canonical exit: 7 Jan 2027 (T+90)
- 3,350 sharesShareXHKGHKEX:DA20261006E00513
- 510 shares@ HK$68.89820.0001% mcap100.0% of flowShareXHKGHKEX:DA20260911E00478
- 1,650 shares@ HK$68.89820.0004% mcap100.0% of flowShareXHKGHKEX:DA20260911E00491
- 540 shares@ HK$68.89820.0001% mcap100.0% of flowShareXHKGHKEX:DA20260911E00465
- 1,650 shares@ HK$68.89820.0004% mcap100.0% of flowShareXHKGHKEX:DA20260911E00448
- 1,650 sharesShareXHKGHKEX:DA20260902E00396
- 1,650 sharesShareXHKGHKEX:DA20260902E00397
- 1,650 sharesShareXHKGHKEX:DA20260902E00395
- 1,650 sharesShareXHKGHKEX:DA20260902E00393
- 1,500,000 sharesShareXHKGHKEX:DA20260722E00566Canonical exit: 15 Oct 2026 (T+90)
- 91,445 shares@ HK$65.72840.019% mcap100.0% of flowShareXHKGHKEX:DA20260710E00528
- 375,000 sharesShareXHKGHKEX:DA20260702E00451
13 of 13 declarations
About Shanghai Henlius Biotech, Inc. - H Shares
Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on the development of biosimilar drugs. It specializes in the research and commercialization of treatments for cancer and other serious diseases.
